<DOC>
	<DOCNO>NCT00006472</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Giving chemotherapy drug radiation therapy surgery may shrink tumor remove surgery . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus radiation therapy give surgery treat patient stage I , stage II , stage III esophageal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Followed By Surgery Treating Patients With Stage I , Stage II , Stage III Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine total response rate patient stage I , II , III esophageal cancer treat paclitaxel , carboplatin , fluorouracil concurrent radiotherapy follow surgical resection . II . Determine overall survival patient treat regimen . II . Determine toxicity regimen patient population . OUTLINE : Patients receive paclitaxel IV 1 hour follow carboplatin IV 30 minute day 1 22 , fluorouracil IV continuously day 1-42 . Patients undergo radiotherapy concurrently chemotherapy daily 5 day week 5 week . Patients undergo surgical resection within 3-5 week follow completion therapy . Patients follow every 3 month 6 month , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 47 patient accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma adenocarcinoma upper , middle , low third esophagus Stage I , II , III disease Measurable disease No distant metastases Negative liver biopsy Negative bone scan unless due benign disease No tracheobronchial involvement No vocal cord paralysis No phrenic nerve involvement No celiac axis lymph node involvement unless due primary cancer gastroesophageal junction No evidence disseminate cancer PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 1.5 mg/dL SGOT/SGPT great 2 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : No uncontrolled severe cardiovascular disease No congestive heart failure No myocardial infarction within past 6 month No severe uncontrolled hypertension ( systolic great 150 mmHg diastolic great 100 mmHg ) Pulmonary : FEV1/FVC least 75 % predict Arterial blood saturation least 92 % Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy except curatively treat nonmelanoma skin cancer carcinoma situ cervix No serious medical illness would limit survival few 2 year No active uncontrolled bacterial , viral , fungal infection No active uncontrolled duodenal ulcer No psychiatric disorder would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior chest radiotherapy Surgery : No prior surgical resection tumor Other : No prior therapy esophageal cancer</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2002</verification_date>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>